Respiratory syncytial virus (RSV) infections in paediatric transplant patients

CANADIAN PAEDIATRIC SURVEILLANCE PROGRAM

2305 St. Laurent Blvd. Ottawa, ON K1G 4J8 Tel: 613-526-9397, ext. 239

Fax: 613-526-3332 cpsp@cps.ca www.cps.ca/cpsp

REPORTING INFORMATION (To be completed by the CPSP Senior Coordinator) Report number: Month of reporting: Province: Today's date:

Please complete the following sections for the case identified above. Strict confidentiality of information will be assured.

CASE DEFINITION FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN PAEDIATRIC TRANSPLANT PATIENTS

Report all inpatients and outpatients less than 18 years of age who have:

- a laboratory-confirmed respiratory syncytial virus (RSV) infection
- received a solid organ transplantation (SOT) or a haematopoietic stem cell transplantation (HSCT) within the two previous years.

	Month first seen				
SEC	TION 1 – DEMOGRAPHIC INFORMATION				
1.1	Date of birth: / / 1.2				
1.3	Gestational age: term prematurity specify: weeks unknown				
1.4	Ethnicity: First Nations Innu Inuit Métis Asian Black Caucasian				
	Latin American Middle Eastern Other (specify): Unknown				
1.5	Province/Territory of residence:				
	Urban Rural (population <1,000) Unknown				
1.6	Total number of children in the home (excluding patient) Unknown				
1.7	Number of children ≤5 years of age in the home (excluding patient) Unknown				
1.8	Does a household member smoke: Yes No Unknown				
	in the house?				
	in the automobile?				
1.9	Does patient attend day care or home care with ≥4 children (including patient)?				
SEC	TION 2 – PAST HISTORY				
2.1	Does the child have any type of chronic lung disease?				
	If yes, specify: Chronic lung disease of prematurity requiring medical therapy in the preceding 6 months				
	Other lung disease requiring chronic oxygen in the preceding 6 months CF				
	Other (specify type):				

SEC	TION 2 – PAST HISTORY (cont'd)	V .		11-1-
0.0		Yes	No	Unknown
2.2	Has this child had a tracheostomy in the preceding 12 months?			
2.3	Does the child have:			
	2.3.1 hemodynamically significant heart disease post-transplant?2.3.2 Down syndrome?			
	2.3.2 Down syndrome?2.3.3 evidence for pulmonary aspiration in the year prior to RSV infection?			
	2.3.4 a neurologic condition with a risk for aspiration?			
SEC	TION 3 – TRANSPLANTATION AND TREATMENT			
3.1	Date of transplant (if more than one, specify most recent date): / /	YYYY	_	
3.2	Type of transplant: liver kidney heart lung small be	owel		
	multiple organs, specify:		_	
	autologous HSCT allogeneic HSCT			
0.0	5:11 1:11	Yes	No	Unknown
3.3	Did the child receive induction anti-lymphocyte therapy?			
	antilymphocyte globulin (Thymoglobulin®)			
	• muromonab-CD3 (OKT3®)			
	basiliximab (Simulect®) dadimumah (Zananga)			
0.4	daclizumab (Zenaprex®) Lea the shill be an treated for reinsting 2.			
3.4	Has the child been treated for rejection?			
	If yes, specify date of last treatment: / /			
3.5	Does the child have evidence for Graft Versus Host Disease (GVHD)?			
SEC	TION 4 – RSV PRESENTATION AND TREATMENT			
4.1	Date of RSV diagnosis: / / Inpatient Outpatient			
4.2	Did the child have a lower respiratory tract infection?			
	(defined as need for oxygen or increased oxygen, wheezing, crepitations, or CXR changes)			
4.3	Was the RSV infection nosocomial?			
4.5	4.3.1 Symptoms starting in hospital >2 days after admission			
	4.3.2 Symptoms starting at home <2 days of hospital discharge			
4.4	Was the child admitted because of RSV?			
7.7	If yes, number of days in hospital:			
4.5	Was the child admitted to ICU because of RSV?			
4.0	If yes, number of days:			
4.6	Was the child already in ICU for other reasons?			
4.0	If yes, number of days in ICU due to RSV:			
4.7	Was the child ventilated because of RSV?			
7.1	If yes, number of days:			
4.8	Did the child require ECMO (ECLS) because of RSV?			
₹.0	If yes, number of days:			
	11 y 00, 11 dilibor of days			

SEC	TION 4 – RSV PRESENTATION AND TREATMENT (cont'd)	Yes	No	Unknown
4.9	Did the child receive intravenous immunoglobulin (IVIG) as treatment of RSV?			
4.10	Did the child receive palivizumab as treatment for RSV?			
4.11	Did the child receive ribavirin as therapy for RSV?			
	If yes, provide route and duration:			
4.12	Current immunosuppression at time of RSV (check all that apply):			
	Tacrolimus/FK-506 Cyclosporin A (Sandimmune®, Neoral®)			
	Mycophenolate mofetil/MMF Azathioprine Sirolimus/rapamycin			
	Steroids specify dose, mg/kg/day: dose unknown			
	Others, specify drug names:			
SEC	TION 5 – MANAGEMENT			
5.1	Was palivizumab recommended post transplant for this patient?			
	If yes, specify: for the current RSV season			
	only for the preceding RSV season			
5.2	Did this patient receive palivizumab within 4 weeks prior to RSV diagnosis?			
	If yes, specify date of last dose: / / DD MM YYYY			
5 2				
5.3	Was the transplant centre made aware of the RSV infection?			
SEC	TION 6 - OUTCOME			
6.1	Patient still in hospital:			
	6.1.1 Patient transferred to another facility:			
	If yes, please specify:			
6.3	Patient discharged home:			
	If yes, with no short-term sequelae from RSV			
	with home oxygen due to RSV			
	with other RSV-related sequelae at discharge; specify:			
6.4	Patient is deceased			
	If yes, age at time of death: weeks / months			
	If yes, cause of death during admission:			
	6.4.1 RSV infection			
	6.4.2 RSV contributing to death but not the primary cause			
	6.4.3 RSV did not contribute to death			
	6.4.4 Other cause, specify:			
6.5	Lost to follow-up			
	Logran to be contacted by the received to un for frintless information			
	I agree to be contacted by the research team for further information.	ation		

SECTION 7 – REPORTING PHYSICIAN

First name	Surname		
Address			
City	Province	Postal code	
Telephone number	Fax numb	per	
E-mail	Date com	pleted	

Thank you for completing this form.

(RSV 2010-09)